Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.78 USD | +1.71% |
|
-2.20% | -38.62% |
May. 15 | Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents | CI |
May. 14 | William Blair Upgrades Neuronetics to Outperform From Market Perform | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 83.66 | 210.8 | 117.6 | 187 | 83.91 | 53.4 | - | - |
Enterprise Value (EV) 1 | 83.66 | 210.8 | 117.6 | 187 | 83.91 | 53.4 | 53.4 | 53.4 |
P/E ratio | -2.84 x | -7.61 x | -3.66 x | -4.98 x | -2.76 x | -1.92 x | -2.75 x | -4.51 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 1.34 x | 4.28 x | 2.13 x | 2.87 x | 1.18 x | 0.67 x | 0.59 x | 0.51 x |
EV / Revenue | 1.34 x | 4.28 x | 2.13 x | 2.87 x | 1.18 x | 0.67 x | 0.59 x | 0.51 x |
EV / EBITDA | -3.44 x | -9.59 x | -4.5 x | -7.57 x | -2.94 x | -4.53 x | -22.2 x | 14.4 x |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 18,632 | 18,975 | 26,368 | 27,221 | 28,933 | 29,998 | - | - |
Reference price 2 | 4.490 | 11.11 | 4.460 | 6.870 | 2.900 | 1.780 | 1.780 | 1.780 |
Announcement Date | 3/3/20 | 3/2/21 | 3/8/22 | 3/7/23 | 3/5/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 62.66 | 49.24 | 55.31 | 65.21 | 71.35 | 79.14 | 89.83 | 104 |
EBITDA 1 | -24.29 | -21.99 | -26.11 | -24.72 | -28.55 | -11.8 | -2.4 | 3.7 |
EBIT 1 | -26.93 | -22.31 | -27.56 | -35.11 | -30.55 | -21.38 | -13.65 | -7.542 |
Operating Margin | -42.98% | -45.3% | -49.83% | -53.85% | -42.82% | -27.02% | -15.19% | -7.25% |
Earnings before Tax (EBT) 1 | -29.04 | -27.45 | -31.19 | -37.16 | -30.19 | -28.27 | -20.92 | -13.99 |
Net income 1 | -29.04 | -27.45 | -31.19 | -37.16 | -30.19 | -27.91 | -20.25 | -13.99 |
Net margin | -46.35% | -55.75% | -56.39% | -56.99% | -42.31% | -35.27% | -22.54% | -13.46% |
EPS 2 | -1.580 | -1.460 | -1.220 | -1.380 | -1.050 | -0.9250 | -0.6475 | -0.3950 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/3/20 | 3/2/21 | 3/8/22 | 3/7/23 | 3/5/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 15.02 | 14.18 | 16.33 | 16.5 | 18.2 | 15.54 | 17.61 | 17.84 | 20.31 | 17.42 | 18.65 | 20.12 | 22.99 | 19.67 | 21.57 |
EBITDA 1 | -6.279 | -7.564 | -7.255 | -4.889 | -5.009 | -7.586 | -4.828 | -6.517 | -3.924 | -4.961 | -3.6 | -2.7 | -0.6 | - | - |
EBIT 1 | -6.908 | -10.14 | -9.796 | -7.454 | -7.726 | -9.907 | -7.349 | -8.871 | -4.427 | -6.859 | -6.196 | -5.555 | -3.092 | -5.409 | -4.561 |
Operating Margin | -45.99% | -71.47% | -59.99% | -45.18% | -42.46% | -63.75% | -41.73% | -49.71% | -21.79% | -39.38% | -33.22% | -27.61% | -13.45% | -27.5% | -21.15% |
Earnings before Tax (EBT) 1 | -7.635 | -10.84 | -10.42 | -7.609 | -8.289 | -10.52 | -4.901 | -9.391 | -5.377 | -7.873 | -8.06 | -7.418 | -4.956 | -7.235 | -6.387 |
Net income 1 | -7.635 | -10.84 | -10.42 | -7.609 | -8.289 | -10.52 | -4.901 | -9.391 | -5.377 | -7.873 | -8.06 | -7.418 | -4.956 | -7.235 | -6.387 |
Net margin | -50.83% | -76.43% | -63.83% | -46.12% | -45.55% | -67.7% | -27.83% | -52.63% | -26.47% | -45.2% | -43.21% | -36.87% | -21.55% | -36.79% | -29.62% |
EPS 2 | -0.2900 | -0.4100 | -0.3900 | -0.2800 | -0.3000 | -0.3800 | -0.1700 | -0.3300 | -0.1900 | -0.2700 | -0.2700 | -0.2400 | -0.1550 | -0.2100 | -0.1600 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/8/22 | 5/12/22 | 8/2/22 | 11/8/22 | 3/7/23 | 5/9/23 | 8/8/23 | 11/7/23 | 3/5/24 | 5/7/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 3/3/20 | 3/2/21 | 3/8/22 | 3/7/23 | 3/5/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.62% | 53.4M | |
+0.91% | 204B | |
+3.74% | 178B | |
+28.89% | 154B | |
+31.66% | 112B | |
+1.29% | 64.32B | |
+19.45% | 54.88B | |
-2.27% | 47.24B | |
-9.28% | 36.8B | |
-0.10% | 35.26B |
- Stock Market
- Equities
- STIM Stock
- Financials Neuronetics, Inc.